We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TransEnterix (TRXC) Reports Wider-Than-Expected Loss in Q4
Read MoreHide Full Article
TransEnterix, Inc. reported a loss of 12 cents per share in the fourth quarter of 2016, wider than the Zacks Consensus Estimate of a loss of 11 cents. The company had incurred a loss of 13 cents in the year-ago quarter.
In the reported quarter, TransEnterix posted total revenues of $53,000 versus no revenue in the year-ago quarter. Revenues consisted entirely of the recognition of deferred and services revenues associated with existing placements.
Stock Performance
The price performance of the stock has been favorable in the last three months. TransEnterix registered a loss of 6.43%, underperforming the Zacks classified Medical - Instruments sub-industry’s gain of almost 8.55%.
Operational Details
In the reported quarter, total operating expenses were $14.4 million compared with $13.9 million in the year-ago quarter.
Research and development expense decreased from $8.6 million in the year-ago quarter to $7.5 million. This was primarily due to the timing of work conducted to prepare FDA submission.
Sales and marketing expenses in the reported quarter increased to approximately $3.6 million from $1.7 million in the prior-year period. This was primarily related to headcount growth and other expenses from commercial expansion in Europe.
General and administrative expenses in the reported quarter increased to approximately $2.9 million from $2.2 million in the prior-year period. This was primarily due to expansion in support of our European commercial investment.
Overall, net loss came in at $14 million compared with a net loss of $13.6 million in the prior-year period.
Financial Condition
As of Dec 31, 2016, TransEnterix had $24.2 million in cash and cash equivalents versus $38.4 million as of Dec 31, 2015.
TransEnterix, Inc. Price, Consensus and EPS Surprise
IDEXX Laboratories has a long-term expected earnings growth rate of approximately 15.04%. Notably, the stock represents an impressive one-year return of 90.6%.
Avinger projects sales growth of 30.7% for the current year. Additionally, the company posted a positive earnings surprise of 27% in the last quarter.
Fluidigm has a long-term expected earnings growth rate of 25%. Additionally, the company posted a positive earnings surprise of 1.6% in the last quarter.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
TransEnterix (TRXC) Reports Wider-Than-Expected Loss in Q4
TransEnterix, Inc. reported a loss of 12 cents per share in the fourth quarter of 2016, wider than the Zacks Consensus Estimate of a loss of 11 cents. The company had incurred a loss of 13 cents in the year-ago quarter.
In the reported quarter, TransEnterix posted total revenues of $53,000 versus no revenue in the year-ago quarter. Revenues consisted entirely of the recognition of deferred and services revenues associated with existing placements.
Stock Performance
The price performance of the stock has been favorable in the last three months. TransEnterix registered a loss of 6.43%, underperforming the Zacks classified Medical - Instruments sub-industry’s gain of almost 8.55%.
Operational Details
In the reported quarter, total operating expenses were $14.4 million compared with $13.9 million in the year-ago quarter.
Research and development expense decreased from $8.6 million in the year-ago quarter to $7.5 million. This was primarily due to the timing of work conducted to prepare FDA submission.
Sales and marketing expenses in the reported quarter increased to approximately $3.6 million from $1.7 million in the prior-year period. This was primarily related to headcount growth and other expenses from commercial expansion in Europe.
General and administrative expenses in the reported quarter increased to approximately $2.9 million from $2.2 million in the prior-year period. This was primarily due to expansion in support of our European commercial investment.
Overall, net loss came in at $14 million compared with a net loss of $13.6 million in the prior-year period.
Financial Condition
As of Dec 31, 2016, TransEnterix had $24.2 million in cash and cash equivalents versus $38.4 million as of Dec 31, 2015.
TransEnterix, Inc. Price, Consensus and EPS Surprise
TransEnterix, Inc. Price, Consensus and EPS Surprise | TransEnterix, Inc. Quote
Zacks Rank & Key Picks
Currently, TransEnterix carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the broader medical sector include IDEXX Laboratories, Inc. (IDXX - Free Report) , Avinger, Inc. (AVGR - Free Report) and Fluidigm Corp. . All the three stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here.
IDEXX Laboratories has a long-term expected earnings growth rate of approximately 15.04%. Notably, the stock represents an impressive one-year return of 90.6%.
Avinger projects sales growth of 30.7% for the current year. Additionally, the company posted a positive earnings surprise of 27% in the last quarter.
Fluidigm has a long-term expected earnings growth rate of 25%. Additionally, the company posted a positive earnings surprise of 1.6% in the last quarter.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>